Last updated 2026-07-27
- Went public on NASDAQ (NRXP), Nov 2017
- Raised $150M Follow-on PO, Dec 2025
- Raised $25M PIPE, Feb 2022
Total raised
$406.6M
Last: Public Offering 2026-06
Stage
Public
Founded
2015
Headcount
29
HQ
Wilmington, United States
Sector
Health Tech & Life Sciences
About
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRx Pharmaceuticals also operates HOPE Therapeutics, a subsidiary establishing a national network of interventional psychiatry clinics.
Funding history · 24 rounds · $406.6M total
2026-02
Follow-on PO
$20.0M
2025-12
Follow-on PO
$150.0M
2025-08
Follow-on PO
$6.5M
2025-04
Follow-on PO
$20.0M
2025-01
PIPE
$2.0M
2025-01
Debt Financing
$3.5M
2024-10
Debt Financing
$5.0M
2024-08
Debt Financing
$15.0M
2024-02
Follow-on PO
$4.9M
2024-02
PIPE
$1.5M
2023-09
PIPE
$1.2M
2023-08
Follow-on PO
$2.0M
2023-06
Follow-on PO
$6.3M
2023-03
Follow-on PO
$2.9M
2022-12
Follow-on PO
$20.0M
2022-11
Debt Financing
$11.0M
2022-06
Follow-on PO
Undisclosed
2022-02
PIPE
$25.0M
2021-08
Follow-on PO
$30.0M
2021-03
PIPE
$10.0M
2019-07
Debt Financing
Undisclosed
2018-11
Debt Financing
$690K
2017-11
IPO
$60.0M
2017-11
PIPE
$9.2M
Headcount over time
From 10 (2019-03) to 14 (2026-03) · +4 (+40%) · 37 points · source: Finder history + radar grounding
Q&A
- What is NRx Pharmaceuticals' primary focus?
- NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD.
- What is the current employee count for NRx Pharmaceuticals?
- NRx Pharmaceuticals currently has 11-50 employees.
- What was NRx Pharmaceuticals' most recent funding round?
- NRx Pharmaceuticals completed a Public Offering in February 2026, raising $20,000,001.
- When did NRx Pharmaceuticals go public?
- NRx Pharmaceuticals went public on NASDAQ in May 2021.
- What is the total amount of funding NRx Pharmaceuticals has raised to date?
- NRx Pharmaceuticals has raised a total of $55,335,000 USD.
- What is NRx Pharmaceuticals' subsidiary HOPE Therapeutics doing?
- In September 2025, NRx Pharmaceuticals' subsidiary HOPE Therapeutics closed the acquisition of Dura Medical, which is an initial acquisition in its planned network of interventional psychiatry clinics.
- What is the status of NRx Pharmaceuticals' NRX-100 product?
- In September 2025, NRx Pharmaceuticals re-filed an Abbreviated New Drug Application (ANDA) for KETAFREE™, its preservative-free IV Ketamine (NRX-100).
- What recent FDA designation did NRx Pharmaceuticals receive for NRX-100?
- In August 2025, NRx Pharmaceuticals received FDA Fast Track Designation for NRX-100 for suicidal ideation in patients with depression, including bipolar depression.
- What is NRx Pharmaceuticals' current market capitalization?
- NRx Pharmaceuticals has a market capitalization of $80,229,957 USD.
Team · 2
Jonathan C. Javitt
Founder · Founder
Daniel C. Javitt
Founder · Co-Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business model
B2B
Highlights
1 PatentsVerified
Tags
mental-healthpsychiatrypharmaceuticalsschizophreniachronic-pain
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nrxpharma.com/ |
|---|---|
| linkedin.com/company/10024731 | |
| facebook.com/NRxPharma |
Identifiers & details
| Legal name | NRx Pharmaceuticals, Inc. |
|---|---|
| Founded | 2015-5 |
| Employees (exact) | 29 |
| Offices | Wilmington |
| Market cap | $80.2M |
| Status reason | Public on NASDAQ on May, 2021 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2017-11 | NASDAQ | NRXP | |
| Public Offering | 2026-06 | NASDAQ | NRXP | $20.0M |
Radar intelligence
Web history (Wayback)
| Domain | nrxpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 10 |
|---|